OWKIN is set to use machine learning to augment medical and biology research
OWKIN Socrates is the first data-driven machine learning platform for medi...
How is OWKIN using machine learning to augment medical and biology research?
OWKIN Socrates is the first data-driven machine learning platform for medical research. It is designed to augment medical researchers’ skills and recapture the excitement of research and exploration.
Socrates will help researchers in academia, hospitals and the pharmaceutical industry. The platform is smart and will allow researchers to become machine teachers, without needing to understand the mathematics behind the scenes. The platform learns while the researchers discover, improving its global, collective intelligence.
The underlying machine learning technology is a unique integration of models built upon medical images, genomics and clinical data, allowing for the discovery of biomarkers and mechanisms associated with diseases and treatment outcomes. Our proprietary federated learning technology will enable collaboration among researchers and centres without sharing data or uploading it to the cloud.
Are medical professionals embracing such new tools in such a traditional industry?
The reception has been great. We’ve focused on making our product integrate into clinicians and researcher workflows. Machine learning is part of the next wave of technologies, and Socrates lets medical professionals be a part of that without needing to develop PhD computer science skills. We’ve definitely seen them embrace the tool, to the point where in its beta stage we’re having to be selective as to research questions.
How will the use of this data enhance patient care?
A) One of the key problems facing the pharmaceutical industry is that it isn’t able to fully leverage the data it generates. Another is that access to real-world data is expensive. OWKIN is solving these problems with collective intelligence built on real-world patient-generated data.
We partner with pharmaceutical researchers to use the platform’s knowledge to answer questions that will help cure diseases, without sharing any data from our hospital partners.
A typical use case with pharma would be utilising our technology - and the intelligence pre-trained on real world data - to better understand drug development opportunities using patient cohorts based on drug resistance and toxicities. We can help a company fine-tune patient recruitment in a clinical trial with imaging or other biomarkers. Pharma companies can also purchase predictive models built with real-world data, biomarkers or targets developed with our partners.
Who are some of the providers or organisation’s that OWKIN is working with, etc?
We are working with some of the largest pharmaceutical companies such as Amgen and Roche and have research collaborations with Institut Curie and INSERM (the second largest cancer research organisation in the world after the NCI), among many others.
NHS care homes are better than private, report finds
A new survey has found that 60% of people with parents in NHS care homes believe the quality of care has improved, compared to just 49% of respondents with parents in private care facilities.
The survey was conducted by Kepler Vision Technologies, an AI-driven company formed at the University of Amsterdam. It was carried out among UK adults with parents over the age of 75.
Respondents cited more capable care staff and better monitoring systems as being the main reasons for improvement.
However those who do not have parents in assisted living facilities had a different viewpoint - in this case only 35% of respondents believe that NHS facilities are improving, compared to 32% who believe it is only improving in the private sector.
Only 18% of people whose parents live with them or independently believe care home staff are able to look after residents to a good standard.
Kepler Vision say this difference in opinion is due to perceived budget cuts and financial pressures, with 67% of people commenting that a lack of funding has had a negative effect on care in both NHS and private care facilities.
Other key findings of the survey include:
* Out of those who say quality has declined in care homes, 69% say the NHS is dealing with budget cuts and increased financial pressure, while 65% also said that the private system is dealing with these pressures too
* 55% said that they or their parent have money saved specifically to pay for their future care
* 35% said the idea of their parent in a care home makes them feel frightened, although 32% say it makes them feel secure
* 52% are worried about their parent catching COVID
* 47% are worried about their parent being lonely
* 46% are concerned they could fall over alone
The announcement of this research follows the UK government's decision to delay presenting its social care budget till the autumn.
Commenting on the research, Dr Harro Stokman, CEO of Kepler Vision Technologies said: “While it is good to see that people recognise the importance of staff and face-to-face interaction in elderly care, the huge gap in opinion between those with parents in care and those without shows that there are unfair negative perceptions around the residential care space.
"More can and should be done by care homes to give people the confidence that their relatives will receive the very best care - by highlighting the excellent work of staff and how well they are able to monitor resident’s needs with easy-to-use technology.”